Lu Guangxiu

Professor, chief physician, Xiangya famous doctor, doctoral supervisor, reproductive medicine and medical geneticist, one of the founders of human reproductive engineering in China, director of the National Engineering Research Center of Human Stem Cells, honorary president and chief scientist of CITIC Xiangya Reproductive and Genetic Hospital, director of the National Demonstration Center for the application of genetic Testing Technology - Prepregnancy Diagnosis Center. He was a member of the Standing Committee of the CPPCC National Committee, chairman of the Jiusan Society of Hunan Province, vice chairman of the CPPCC Hunan Province, and director of the Reproductive and Stem Cell Engineering Institute of Central South University.

In the 1980s, Lu Guangxiu established a relatively complete system of human assisted reproductive technology in China, carried out infertility and genetic clinics, and achieved fruitful results:

A human sperm bank was established in 1981. In 1983, a baby was artificially inseminated with frozen semen.

Two IVF babies were born in 1988; In 1990, the mouse embryo genetic diagnosis model of preimplantation embryo was established and successfully applied in human.

In 1991, a normal baby was born after the treatment of malformed sperm separation.

A sperm microinsemination model was established in 1993.

In 2000, a "test tube baby" was born after ultra-rapid frozen embryo transfer.

In 2005, she gave birth to a normal baby who was diagnosed before pregnancy and excluded Duchenne muscular dystrophy.

In 2012, PGD/PGS test-tube baby with whole genome sequencing technology was born; In 2015, "cancer-free baby" was born;

In 2016, a healthy baby was born after MicroSeq excluded chromosome balance translocation.

Up to now, the hospital has a total of more than 220,000 healthy babies born with artificial assisted pregnancy. According to Nature in 2017, the amount of assisted reproductive treatment in a year is equivalent to about 1/4 of the United States, which has won the trust and praise of patients. She and her team have been able to block more than 1064 kinds of single-gene diseases, and initially achieved the goal of "positive eugenics".

In the field of human embryonic stem cell research and application, Professor Lu Guangxiu led the research team to become the National Human stem Cell Engineering Center approved by the National Development and Reform Commission in 2004, and became the key laboratory of human Stem cell and reproductive engineering approved by the Ministry of Health in 2005. The center constructed human somatic cell cloned blastocyst, the research has been reported by the Wall Street newspaper and the British Times column, "Nature" and many other international authoritative academic journals to her introduction, has attracted widespread attention from international peers. In addition, the center has established a human embryonic stem cell line and has become an embryonic stem cell bank with independent intellectual property rights, with a stock of more than 500 human embryonic stem cells, providing sufficient seed sources for regenerative medicine.

Due to her outstanding contributions in the field of reproductive medicine and stem cell research, she has won the second prize of National Science and Technology Progress twice. And won the "national outstanding contribution of science and technology experts", "National March 8 Red Flag Bearer", "China's top Ten women", "National Advanced workers", "National May 1 Labor Medal", "National excellent Teacher", "Chinese Population Award", "National 93 Model", "National famous Doctor", "National". China Good Man List Dedicated Good Man ", "Hunan Province Outstanding Contribution to Science and Technology Award", "Hunan Province moral model" and other honors.

She has undertaken a number of national research projects including key projects of the National Natural Science Foundation, 863 and 973. Six monographs have been published, among which "Human Reproduction and Reproductive Engineering" is the earliest monograph on human assisted reproductive technology in China. As of June 2017, 572 papers have been published, including 80 papers in SCI journals, and 24 international and domestic patents have been obtained. As a doctoral supervisor in developmental biology, genetics, reproductive medicine, stem cell and regenerative medicine, and bioethics, she has trained a large number of professionals in human assisted reproduction and stem cell research for our country.